

Article title

Absorption, distribution, metabolism, and excretion of the novel helicase-primase inhibitor, amenamevir (ASP2151), in rodents

Journal name

European Journal of Drug Metabolism and Pharmacokinetics

Authors

Yoshiaki Ohtsu, Yoko Susaki, and Kiyoshi Noguchi

Corresponding author

Yoshiaki Ohtsu

Analysis & Pharmacokinetics Research Laboratories, Astellas Pharma Inc.

yoshiaki.ohtsu@zoho.com

Caption

Electronic supplementary material 1

Tissue to plasma concentration ratios

Supplementary Table 1. Tissue to plasma concentration ratios after single oral administration of ^{14}C -amenamevir to mice at 3 mg/kg

Tissue	Tissue to plasma concentration ratios		
	0.5 h	1 h	4 h
Blood	0.9	0.9	0.9
Plasma	1.0	1.0	1.0
Brain	0.1	0.1	0.1
Spinal cord	0.1	0.1	0.1
Hypophysis	2.4	2.2	3.1
Eyes	0.4	0.5	0.6
Harderian glands	5.4	5.6	5.4
Submaxillary glands	2.3	2.3	2.1
Thyroid gland	2.7	2.1	2.0
Thymus	1.1	1.3	1.2
Heart	2.4	2.4	2.2
Lungs	1.9	1.6	1.8
Liver	24.9	20.1	21.7

Spleen	1.5	1.4	1.5
Pancreas	3.2	2.9	3.0
Adrenals	2.1	2.4	1.8
Kidneys	5.3	5.0	5.3
Epididymides	0.9	0.9	1.6
Testes	0.1	0.2	0.5
Skeletal muscle	1.1	1.1	1.1
Skin	0.6	0.6	0.8
Fat	0.9	1.0	1.0
Femur	0.2	0.3	0.2
Urinary bladder	0.9	1.0	1.6
Stomach	16.0	2.5	5.0
Small intestine	15.4	15.0	10.0
Large intestine	1.4	2.9	18.4

Each value represents the mean of concentration ratios from three animals. Concentration ratios at 24 h were not calculated as the plasma concentrations at 24 h were below the limit of quantitation.